Targeted radiotherapy is driving over $30 billion in pharma deals. ATNM-400 targets Steap-1, addressing major cancer treatment gaps. Preclinical data suggests ATNM-400 outperforms existing therapies in resistant cancers. Multifaceted indications strengthen ATNM's market position across key cancers. Strong clinical signals may elevate ATNM as a leading oncology player.
Actinium initiates Phase 1 trial for ATNM-400 in South Africa targeting B7-H3. The trial highlights the rising interest in alpha radiotherapy for cancer treatment. ATNM-400 shows strong preclinical anti-tumor activity across major solid tumors. B7-H3's prevalence in tumors makes it a key target for therapy. Conducting trials in South Africa boosts Actinium's global development strategy.
